I ntroduction: Fluoroscopy is traditionally used in atrial transseptal puncture (TSP); however fluoroscopy exposes patient and physician to excess radiation. Here, we describe a feasibility study of a zero-fluoroscopy transseptal puncture (ZFTSP) technique utilising electroanatomical mapping (EAM) and intracardiac echo (ICE) in a small case series of patients undergoing ablation for atrial fibrillation (AF). We then compare this technique to other established ZFTSP techniques for paroxysmal AF ablation. Methods: Seven patients received ZFTSP. An Acunav™ ICE catheter (Biosense Webster Inc., California, US) was placed in the right atrium, then an Agilis™ sheath (St. Jude Medical, Saint Paul, Minnesota, US) was established into the inferior vena cava. A ThermoCool ® SmartTouch™ catheter (Biosense Webster Inc., California, US) was inserted through the Agilis to map the fossa ovalis. Mapping catheter exchange for dilator and needle allowed for facile ZFTSP. AF outcome, fluoroscopy times, and procedure times were compared with eight age-matched control patients. Results: There were no significant differences in age, body mass index (BMI) or AF duration between the two groups and no immediate complications. ZFTSP procedure time was 183.9±33.7 minutes versus 293.13±129.9 minutes for TSP-only controls (p=0.05). Fluoroscopy time was 17.5±14.1 minutes in ZFTSP patients versus 73.4±50.3 minutes in controls (p=0.01). AF recurrence in ZFTSP patients was 14% versus 25% in controls. Conclusion: ZFTSP utilising ICE and EAM is safe, effective, and time-efficient. There is a small but significant reduction in radiation exposure to patient and physician by the use of this technique.
The atrial transseptal puncture (TSP) technique is an indispensable procedure in the invasive cardiac catheterisation laboratory. TSP was initially developed in 1959 by Ross, Braunwald and Morrow at the National Institutes of Health, to allow for catheter access to the left atrium (LA) and left ventricle (LV) for the evaluation of valvular heart disease. 1 However, today the need for procedural access to the left heart has expanded to include variety of cardiac conditions, which include: electrophysiological mapping of the left heart, catheter ablation of tachycardias, percutaneous mitral valvuloplasty, left atrial appendage exclusion and haemodynamic measurements in chambers with entry limited by prostheses. 2 Thus, in recent years there has been an exponential increase in the use of TSP for the treatment of left-sided cardiac disease.
Currently, the most common technique used for TSP is the Brockenbrough technique, which utilises fluoroscopy for sheath placement and septal puncture. 3 However, with new imaging technologies including electroanatomical mapping (EAM) and intracardiac echocardiography (ICE), the risk-to-benefit ratio of using fluoroscopic TSP versus standard procedural risk remains unknown. There have been several recent reports of zero-fluoroscopy approaches to the ablation of atrial arrhythmias. [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] However, the combined use of ICE and EAM to map the interatrial septum and set the TSP needle, has not been described in these procedures. Here, we describe a feasibility study to evaluate a completely zero-fluoroscopy technique for TSP (ZFTSP), in patients undergoing ablation for atrial fibrillation (AF) Research Electrophysiology
Methods

Study population and design
We performed a retrospective analysis of patients with paroxysmal or persistent AF who previously elected to have a pulmonary vein isolation procedure due to failure of at least one antiarrhythmic drug (AAD).
Outcomes of patients who received fluoroscopy as part of the TSP were compared with patients in which fluoroscopy was not used due to the use of the ZFTSP technique. Seven ZFTSP patients were compared with eight age-matched TSP controls with fluoroscopy. The study protocol was reviewed and approved by the Institutional Review Boards of the Texas Heart Institute at Baylor College of Medicine.
Procedure technique
The technique for ZFTSP requires a ThermoCool SmartTouch catheter, 
Statistical analysis
5-Fr Agilis sheath, and (D) exchange of Agilis dilator and J-wire for ablation catheter, which is advanced to the fossa ovalis. (E) Electroanatomical mapping of the atrial septal fossa ovalis yields a targeted map for placement of the mapping catheter just inferior to the fossa, and is confirmed by (F) intracardiac echocardiography (ICE).
A
Results
A total of seven patients received ZFTSP. The success rate of performing ZFTSP was 100% (7/7), and there were no redo ZFTSP procedures required. There were no significant baseline differences in age, BMI, or pre-procedural AF duration versus eight age-matched controls. ZFTSP procedure time was 183.9 ± 33.7 minutes versus 293.1 ± 129.9 in controls ( 
Discussion
The main finding of our feasibility study is that a combination of ICE and intracardiac Carto mapping may be used to accurately "set" the transseptal sheath, which may then cross the inter-atrial septum using the usual dilator and needle, without the use of fluoroscopy. This is made possible by technological improvements in EAM, force-sensing ablation catheters, and ICE. The use of this technique bypasses one of the major limitations of fluoroscopy, namely its inability to accurately identify endocardial structures in detail, 14 and it also reduces procedural exposure to radiation.
Previous zero-fluoroscopy approaches to the transseptal technique have used a variety of approaches to TSP ( Table 2) . [4] [5] [6] [7] [9] [10] [11] [12] [13] [15] [16] [17] [18] [19] Kühne et al. advocate using transesophageal echocardiography (TEE) prior to TSP access, 10 whereas several groups describe intra-procedural TEE-guided TSP access with a high degree (97-100%) of AF-free event rates during respective follow-up periods. 13, 16, 17 Other groups have described TEE-guided TSP in combination with fluoroscopy to minimise radiation exposure, however reported outcomes from this approach demonstrated comparatively reduced AF-free success rates (75-85%). 4, 5, 12 No groups have reported EAM-only ZFTSP access, but Clark et al. have demonstrated that EAM-guided TSP access combined with fluoroscopy is feasible. 6 Reddy et al. demonstrated that ICE-guided ZFTSP yielded 90% AF-free success rates at 6.1 months;
Montgomery et al. follow-up results using the same approach are pending at this time.
11,19
The benefits of our ZFTSP approach to existing techniques include EAM of the relevant portions of the inter-atrial septum, improved accuracy of transseptal sheath placement and anatomical mapping of the site of puncture, which may be useful for re-establishing transseptal access if the sheath is withdrawn from the LA. Additionally, our ZFTSP technique contributes to the long-term goals of reducing ionising radiation exposure to both patient and staff to "As Low As Reasonably Achievable" (ALARA). 20 The risks of chronic radiation exposure have been well established in both patients and medical professionals. [21] [22] [23] [24] The risk to interventional cardiologists is most likely the highest among medical professionals because they have been noted to receive more chronic total radiation than any other medical staff using x-ray imaging. 25, 26 Cancer risk among interventional physicians using fluoroscopy remains a controversial topic, but it is receiving increasing attention within the medical literature. For example, recent studies have shown that medical professionals utilising fluoroscopy have an increase in the number of glioblastoma mulitforme, meningiomas and astrocytomas to be associated with their radiation exposures. [27] [28] [29] [30] Additionally, a recent cohort has reported 31 cases of interventionists with brain cancer. 31 These observational studies do not yet prove that interventional procedures cause head and neck cancers among medical professionals, but do highlight a growing concern that will need to be addressed in prospective, randomised trials. 32 The prevalence of spinal disc disease among interventional cardiologists was well described by Ross et al. who showed that cardiologists, versus orthopaedic surgeons and rheumatologists, had the greatest number of complaints for axial skeletal injuries and number of work-days missed secondary to back and neck pain. 33 Efforts to reduce orthopaedic strain and improve radiation protection also include the radiation protection cabin 34 and the Biotronik Zero-Gravity System (Biotronik, Berlin, Germany). By implementing a fluoroscopy-independent method for cardiac procedures, and utilising an external radiation framework when fluoroscopy is absolutely necessary, interventional cardiologists may gain significant advantage by relieving the risk of orthopaedic complications.
(B) Disappearance of the mapping catheter by electroanatomical mapping (EAM) corresponds to proximity of the Agilis to the atrial septum (left), and is confirmed by ICE (right). (C) Cartoon diagram of Agilis sheath crossing the atrial septum, (D) with corresponding EAM (left) and ICE (right) images. (E) Insertion of the mapping catheter can be used to confirm LA placement, (F) as well as injection of agitated saline through the catheter.
Limitations of our study include the risk of the "set" sheath migrating up the septal wall after the mapping catheter is removed in exchange for the transseptal dilator and needle. Although this did not occur during our performance of this technique, this is a legitimate concern that may increase risk of perforation if not addressed. This risk may be mitigated by evaluating the position of the sheath on ICE; should there be a change in sheath position detectable on ICE, the sheath may be reset by reintroducing the mapping catheter. Second, in this small group of patients, there were no significant complications, though the technique should be validated and refined in larger cohorts in the future. Additionally, the TSP fluoroscopy times in this small group of patients were higher than previously reported values; 5, 9, 10, 12 this may be due to the assistance of general cardiology fellows, who generally require longer fluoroscopy times for TSP than an experienced cardiologist, and the addition of patients with either paroxysmal or persistent AF, the latter of which may require longer procedure times and fluoroscopy use.
Conclusion
There are several advantages to the zero-fluoroscopy transseptal technique over the current standard of practice. One of the main advantages is the elimination of radiation exposure to both patient and operator. Secondly, the use of the SmartTouch pressuresensing catheter allows the operator to monitor distal catheter tip pressure accurately and in real-time to avoid inadvertent perforation.
Lastly, the improved EAM technique coupled with ICE allows the operator to better visualise structures, including endocardial structures, which is only partially achievable with fluoroscopy. Our technique takes advantage of three sources of non-fluoroscopic information (echocardiographic anatomical data, 3D anatomical septal mapping and distal catheter tip force sensing) to accurately determine the best site for puncture, reliably deliver the transseptal sheath to this site, and accurate placement of the trans-septal dilator and needle. Further studies to prospectively examine the ZFTSP procedure in a randomised, controlled fashion are forthcoming.
Through this technique, the possibility of a truly non-fluoroscopic procedure may be readily accessible to many active cardiac catheterisation laboratories. q
Article highlights
• Atrial transseptal puncture has traditionally used fluoroscopy to guide catheter placement.
• Here, we present a novel zero-fluoroscopy transseptal puncture (ZFTSP) technique utilising electroanatomical mapping (EAM) and intracardiac echo (ICE).
• The ZFTSP technique in seven patients, was significantly faster than traditional fluoroscopically-based TSP techniques, and reduced radiation exposure during the procedure.
• There was a non-significant trend towards less atrial fibrillation recurrence in this small population, though the study is underpowered to show a statistical significance.
• The ZFTSP procedure holds promise as a novel way to reduce radiation exposure during cardiac procedures requiring atrial TSP.
